Fig. 7: The anti-tumor effect of BCG treatment and anti-PD-L1 combination therapy with nanomotors.

a The treatment schedule and the representative images of sectioned urinary bladder from the bladder cancer model prepared by using MB-49 cells after each treatment (control, BCG, STING and STING@nanomotor) (left) and the corresponding thickness of bladder wall. Data are presented as mean values and error bars represent the S.D. and statistical analysis was performed via two-sided t-test (n = 6 mice per group). b The treatment schedule and the representative images of sectioned urinary bladder from the bladder cancer model after each treatment (control, anti-PD-1, STING@nanomotor and combination) (left) and the corresponding thickness of bladder wall. Data are presented as mean values and error bars represent the S.D. and statistical analysis was performed via two-sided t-test (n = 5 mice per group). c Schematic illustration for the overall mechanism of anti-PD-L1 combination therapy with STING@nanomotor for bladder cancer immunotherapy. Source data are provided as a Source Data file. c created in BioRender. Choi, H. (2024) https://BioRender.com/u13b061.